Immunoscintigraphy

Immunoscintigraphy is a nuclear medicine procedure used to find cancer cells in the body by injecting a radioactively labeled antibody, which binds predominantly to cancer cells and then scanning for concentrations of radioactive emissions.[1][2]

Immunoscintigraphy
Purposedetect cancer cells

Clinical applications

Immunoscintigraphy is performed using a variety of radiopharmaceuticals, for a large range of purposes. Colorectal cancer is one of the most studied areas, with indium-111 or technetium-99m labelled epitopes of the carcinoembryonic antigen.[3] The antibody capromab pendetide reacts with prostate membrane specific antigen (PMSA) and can be labelled with 111In.[4]

See also

References
  1. "Imaging Techniques for the Diagnosis of Ovarian Cancers: Immunoscintigraphy". 21 December 2004.
  2. "Immunoscintigraphy". NCI Dictionary of Cancer Terms. National Cancer Institute. Retrieved 1 June 2017.
  3. Matzku, Siegfried; Stahel, Rolf A (1999). Antibodies in Diagnosis and Therapy. CRC Press. p. 143. ISBN 9789057023101.
  4. Fass, Leonard (August 2008). "Imaging and cancer: A review". Molecular Oncology. 2 (2): 115–152. doi:10.1016/j.molonc.2008.04.001. PMC 5527766. PMID 19383333.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.